NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
ID: 360987Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$475K - $475K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360987
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Director's New Innovator Award Program (DP2 Clinical Trial Optional), aimed at supporting early-stage investigators with innovative research projects that have the potential for significant impact in the biomedical sciences. This grant program encourages applications from a diverse range of eligible applicants, including Indian/Native American Tribal Governments, faith-based organizations, and foreign institutions, with no cost-sharing or matching requirements. The total estimated funding for this program is $23 million, with an award ceiling and floor set at $475,000, and approximately 30 awards expected to be made. Interested applicants can reach out to the NIH Director's New Innovator Award Program via email at NewInnovatorAwards@mail.nih.gov, with applications due by August 19, 2026, and project start dates anticipated for September 30, 2026.

    Point(s) of Contact
    NIH Director's New Innovator Award Program
    Please contact via e-mail.
    NewInnovatorAwards@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional), aimed at supporting early-stage investigators with innovative research proposals that have the potential for significant impact in health-related fields. This grant program encourages applications from individuals demonstrating exceptional creativity, with no preliminary data or detailed experimental plans required, allowing for bold and high-risk research initiatives. The estimated total funding for this program is $37,700,000, with approximately 30 awards expected to be made, and interested applicants should prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release on June 19, 2025, with applications due by August 19, 2025. For further inquiries, applicants can contact Patricia Labosky, Ph.D., at NewInnovatorAwards@mail.nih.gov or by phone at 301-594-4863.
    NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Director's Pioneer Award Program (DP1 Clinical Trial Optional), aimed at supporting individual scientists with exceptional creativity who propose innovative research projects in the biomedical sciences. Applicants are encouraged to present pioneering research that diverges significantly from existing scientific directions, with the potential for substantial impact on areas relevant to NIH's mission. The program has an estimated total funding of $8.1 million, with each award set at $700,000, and anticipates making approximately eight awards. Interested applicants can reach out to the NIH Director's Pioneer Award Program via email at PioneerAwards@mail.nih.gov, with applications due by September 9, 2026, and project start dates expected by September 30, 2026.
    NEI New Innovator Award (DP2 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NEI New Innovator Award, a federal grant aimed at supporting early-stage investigators and postdoctoral candidates in vision research. This opportunity encourages innovative and original research proposals that have the potential to significantly impact the field of vision science, particularly those that explore novel methodologies or interdisciplinary approaches. The program anticipates awarding four grants, with no cost-sharing requirements, and applications are due by May 25, 2026, with an estimated award date of August 2, 2026. For further inquiries, interested applicants can contact Ed Clayton, Ph.D., at 240-987-8255 or via email at Ed.clayton@nih.gov.
    Funding Opportunity for NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Director’s Pioneer Award Program, aimed at supporting innovative research projects with significant potential impact in health-related fields. This grant is designed for individual scientists of exceptional creativity who propose bold and high-risk research initiatives, emphasizing the investigator's qualities and the innovativeness of their proposals. The program anticipates awarding approximately $8.1 million across seven grants, with applications expected to open in June 2025 and close in September 2025. Interested applicants can reach out to Dr. Patricia Labosky at PioneerAwards@mail.nih.gov or by phone at 301-594-4863 for further information.
    NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Director's Early Independence Awards (DP5 Clinical Trial Optional), aimed at supporting promising investigators who wish to embark on independent research immediately following their terminal doctoral degree or post-graduate clinical training. This grant allows recipients to bypass traditional post-doctoral training, thereby accelerating their entry into independent research careers across various areas within the biomedical sciences. With an estimated total program funding of $5.7 million, the NIH anticipates awarding approximately 10 grants, each with a funding amount of $350,000. Interested applicants can reach out to the NIH Director's Early Independence Award Program via email at EarlyIndependence@od.nih.gov, with applications due by September 4, 2026, and awards expected to be announced by September 15, 2026.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIH Director's Early Independence Awards (DP5 Clinical Trial Optional), aimed at supporting promising investigators who wish to pursue independent research shortly after completing their terminal doctoral degree or post-graduate clinical training. Eligible applicants must be in a non-independent research position at the time of application and are limited to submitting two applications per institution, with significant institutional commitment required. This funding opportunity, which has an estimated total program funding of $5,100,000 and expects to award approximately nine grants, is part of the High-Risk, High-Reward Research program and encourages applications across all topics relevant to NIH's mission. Interested applicants can reach out to Becky Miller, Ph.D., at earlyindependence@od.nih.gov or by phone at 301-594-9979, with the application process expected to open on September 10, 2025, and close on October 10, 2025.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators, a federal grant aimed at fostering innovative biomedical research that integrates engineering with life sciences. This funding opportunity, under the R21 Exploratory/Developmental Research Grant mechanism, allows for up to $400,000 in direct costs over a three-year period for projects that require minimal preliminary data, encouraging high-risk, high-reward research. The initiative is designed to enhance diversity within the research community and is open to a wide range of eligible applicants, including various educational institutions and community organizations. Interested parties should note that the application submission period opens on January 16, 2025, and closes on January 8, 2026; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)." This initiative aims to support new investigators from diverse and underrepresented backgrounds in biomedical research, enabling them to conduct small-scale projects that align with the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other participating institutes. The grants, with a maximum budget of $125,000 per year for a project period not exceeding three years, are intended to facilitate the transition of these researchers toward independence while addressing health disparities. Interested applicants must demonstrate that they have had less than $125,000 in direct costs from combined active research funding and can submit proposals starting in early 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-097.html.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators through the R21 Clinical Trial Optional grant mechanism, aimed at fostering innovative research that integrates engineering and physical sciences with biomedical sciences. This funding opportunity encourages exploratory, proof of concept, or high-risk projects, specifically those that do not require extensive preliminary data, allowing applicants to propose novel research approaches. Eligible applicants include a diverse range of institutions and organizations, with funding of up to $400,000 available over a maximum of three years. Interested parties should submit their applications electronically via Grants.gov by the close date of January 7, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.